Inhibition of human organic anion transporter 3 mediated pravastatin transport by gemfibrozil and the metabolites in humans

References

• Abdul-Ghaffar NU, El-Sonbaty MR. Pancreatitis and rhabdomyolysis associated with lovastatin -- gemfibrozil therapy. Journal of Clinical Gastroenterology 1995; 21: 340–341
   PubMed Web of Science ®Google Scholar
• Asberg A. Interactions between cyclosporin and lipid-lowering drugs: Implications for organ transplant recipients. Drugs 2003; 63: 367–378
   PubMed Web of Science ®Google Scholar
• Bruno-Joyce J, Dugas JM, MacCausland OE. Cerivastatin and gemfibrozil-associated rhabdomyolysis. Annals of Pharmacotherapy 2001; 35: 1016–1019
   PubMed Web of Science ®Google Scholar
• Cha SH, Sekine T, Kusuhara H, Yu E, Kim JY, Kim DK, Sugiyama Y, Kanai Y, Endou H. Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. Journal of Biological Chemistry 2000; 275: 4507–4512
   PubMed Web of Science ®Google Scholar
• Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, Endou H. Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Molecular Pharmacology 2001; 59: 1277–1286
   PubMed Web of Science ®Google Scholar
• Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharmaceutical Research 1993; 10: 1093–1095
   PubMed Web of Science ®Google Scholar
• Ekaratanawong S, Anzai N, Jutabha P, Miyazaki H, Noshiro R, Takeda M, Kanai Y, Sophasan S, Endou H. Human organic anion transporter 4 is a renal apical organic anion/dicarboxylate exchanger in the proximal tubules. Journal of Pharmacological Sciences 2004; 94: 297–304
   PubMed Web of Science ®Google Scholar
• Everett DW, Chando TJ, Didonato GC, Singhvi SM, Pan HY, Weinstein SH. Biotransformation of pravastatin sodium in humans. Drug Metabolism and Disposition 1991; 19: 740–748
   PubMed Web of Science ®Google Scholar
• Hasegawa M, Kusuhara H, Sugiyama D, Ito K, Ueda S, Endou H, Sugiyama Y. Functional involvement of rat organic anion transporter 3 (rOat3; Slc22a8) in the renal uptake of organic anions. Journal of Pharmacology and Experimental Therapeutics 2002; 300: 746–753
   PubMed Web of Science ®Google Scholar
• Hatanaka T. Clinical pharmacokinetics of pravastatin: Mechanisms of pharmacokinetic events. Clinical Pharmacokinetics 2000; 39: 397–412
   PubMed Web of Science ®Google Scholar
• Hosoyamada M, Obinata M, Suzuki M, Endou H. Cisplatin-induced toxicity in immortalized renal cell lines established from transgenic mice harboring temperature sensitive SV40 large T-antigen gene. Archives of Toxicology 1996; 70: 284–292
   PubMed Web of Science ®Google Scholar
• Khamdang S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang XL, Enomoto A, Piyachaturawat P, Endou H. Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. Journal of Pharmacological Science 2004; 94: 197–202
   PubMed Web of Science ®Google Scholar
• Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clinical Pharmacology and Therapeutics 2003; 73: 538–544
   PubMed Web of Science ®Google Scholar
• Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, Sugiyama Y. Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. Journal of Pharmacology and Experimental Therapeutics 2005; 314: 1059–1067
   PubMed Web of Science ®Google Scholar
• Mikkaichi T, Suzuki T, Onogawa T, Tanemoto M, Mizutamari H, Okada M, Chaki T, Masuda S, Tokui T, Eto N, et al. Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proceedings of the National Academy of Sciences of the United States of America. 2004; 101: 3569–3574
   Google Scholar
• Nakagawa A, Shigeta A, Iwabuchi H, Horiguchi M, Nakamura K, Takahagi H. Simultaneous determination of gemfibrozil and its metabolites in plasma and urine by a fully automated high performance liquid chromatographic system. Biomedical Chromatography 1991; 5: 68–73
   PubMed Web of Science ®Google Scholar
• Nakai D, Nakagomi R, Furuta Y, Tokui T, Abe T, Ikeda T, Nishimura K. Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. Journal of Pharmacology and Experimental Therapeutics 2001; 297: 861–867
   PubMed Web of Science ®Google Scholar
• Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T, Takane H, Irie S, Kusuhara H, Urasaki Y, et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: Consequences for pravastatin pharmacokinetics. Clinical Pharmacology and Therapeutics 2003; 73: 554–565
   PubMed Web of Science ®Google Scholar
• Ogilvie BW, Zhang D, Li W, Rodrigues AD, Gipson AE, Holsapple J, Toren P, Parkinson A. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: Implications for drug–drug interactions. Drug Metabolism and Disposition 2006; 34: 191–197
   PubMed Web of Science ®Google Scholar
• Okerholm RA, Keeley FJ, Peterson FE, Glazko AJ. The metabolism of gemfibrozil. Proceedings of the Royal Society of Medicine 69(suppl. 2). 1976; 11–14
   Google Scholar
• Prueksaritanont T, Zhao JJ, Ma B, Roadcap BA, Tang C, Qiu Y, Liu L, Lin JH, Pearson PG, Baillie TA. Mechanistic studies on metabolic interactions between gemfibrozil and statins. Journal of Pharmacology and Experimental Therapeutics 2002; 301: 1042–1051
   PubMed Web of Science ®Google Scholar
• Quion JA, Jones PH. Clinical pharmacokinetics of pravastatin. Clinical Pharmacokinetics 1994; 27: 94–103
   PubMed Web of Science ®Google Scholar
• Roca B, Calvo B, Monferrer R. Severe rhabdomyolysis and cerivastatin -- gemfibrozil combination therapy. Annals of Pharmacotherapy 2002; 36: 730–731
   PubMed Web of Science ®Google Scholar
• Sekine T, Miyazaki H, Endou H. Molecular physiology of renal organic anion transporters. Americal Journal of Physiology. Renal Physiology 2006; 290: F251–F261
   Google Scholar
• Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: Drug–drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacology and Therapeutics 2006; 112: 71–105
   PubMed Web of Science ®Google Scholar
• Shitara Y, Itoh T, Sato H, Li AP, Sugiyama Y. Inhibition of transporter-mediated hepatic uptake as a mechanism for drug–drug interaction between cerivastatin and cyclosporin A. Journal of Pharmacology and Experimental Therapeutics 2003; 304: 610–616
   PubMed Web of Science ®Google Scholar
• Shitara Y, Hirano M, Sato H, Sugiyama Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: Analysis of the mechanism of the clinically relevant drug–drug interaction between cerivastatin and gemfibrozil. Journal of Pharmacology and Experimental Therapeutics 2004; 311: 228–236
   PubMed Web of Science ®Google Scholar
• Shitara Y, Sato H, Sugiyama Y. Evaluation of drug–drug interaction in the hepatobiliary and renal transport of drugs. Annual Review of Pharmacology and Toxicology 2005; 45: 689–723
   PubMed Web of Science ®Google Scholar
• Sun W, Wu RR, Van Poelje PD, Enrion MD. Isolation of a family of organic anion transporters from human liver and kidney. Biochemical and Biophysical Research Communications 2001; 283: 417–422
   PubMed Web of Science ®Google Scholar
• Tahara H, Shono M, Kusuhara H, Kinoshita H, Fuse E, Takadate A, Otagiri M, Sugiyama Y. Molecular cloning and functional analyses of OAT1 and OAT3 from cynomolgus monkey kidney. Pharmaceutical Research 2005; 22: 647–660
   PubMed Web of Science ®Google Scholar
• Tahara H, Kusuhara H, Maeda K, Koepsell H, Fuse E, Sugiyama Y. Inhibition of oat3-mediated renal uptake as a mechanism for drug–drug interaction between fexofenadine and probenecid. Drug Metabolism and Disposition 2006; 34: 743–747
   PubMed Web of Science ®Google Scholar
• Takeda M, Noshiro R, Onozato ML, Tojo A, Hasannejad H, Huang XL, Narikawa S, Endou H. Evidence for a role of human organic anion transporters in the muscular side effects of HMG-CoA reductase inhibitors. European Journal of Pharmacology 2004; 483: 133–138
   PubMed Web of Science ®Google Scholar
• Uwai Y, Saito H, Inui K. Interaction between methotrexate and nonsteroidal anti-inflammatory drugs in organic anion transporter. European Journal of Pharmacology 2000; 409: 31–36
   PubMed Web of Science ®Google Scholar